• Open Access

Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss

Authors


  • Disclosure: Farid Saad is a full-time employee of Bayer Pharma, Germany; Ahmad Haider has received payment for data entry from Bayer Pharma, and lecture fees and travel grants from Jenapharm, Germany, and Takeda Pharma, Germany; Gheorghe Doros has received payment for statistical analyses from Bayer Pharma, Germany; Abdulmaged Traish has nothing to disclose.

Abstract

Objective

This study analyzed the effects of normalization of serum testosterone (T) levels on anthropometric parameters in hypogonadal men.

Design and Methods

Open-label, single-center, cumulative, prospective registry study of 255 men (aged 33–69 years, mean 58.02 ± 6.30 years), with T levels below 12.13 nmol/L (mean: 9.93±1.38). 215 men for at least 2 years, 182 for 3 years, 148 for 4, and 116 for at least 5 years were studied. They received parenteral T undecanoate 1,000 mg/12 weeks after an initial interval of 6 weeks.

Results

Body weight (BW) decreased from 106.22 ± 16.93 kg to 90.07 ± 9.51 kg. Waist circumference (WC) reduced from 107.24 ± 9.14 cm to 98.46 ± 7.39 cm. BMI (m/kg2) declined from 33.9 ± 5.51 m/kg2 to 29.13 ± 3.09 m/kg2. All parameters examined were statistically significant with P < 0.0001 versus baseline and versus the previous year over 5 years indicating a continuous weight loss over the full observation period. The mean per cent weight loss after 1 year was 4.16 ± 0.31%, after 2 years 7.54 ± 0.32%, after 3 years 9.23 ± 0.33%, after 4 years 11.42 ± 0.35% and after 5 years 13.57 ± 0.37%.

Conclusions

In an uncontrolled, observational cohort, normalizing serum T to normal physiological levels produced consistent loss of BW, WC, and BMI. These improvements were progressive over the full 5 years of the study.

Ancillary